These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 34784508)

  • 1. Human influenza virus challenge identifies cellular correlates of protection for oral vaccination.
    McIlwain DR; Chen H; Rahil Z; Bidoki NH; Jiang S; Bjornson Z; Kolhatkar NS; Martinez CJ; Gaudillière B; Hedou J; Mukherjee N; Schürch CM; Trejo A; Affrime M; Bock B; Kim K; Liebowitz D; Aghaeepour N; Tucker SN; Nolan GP
    Cell Host Microbe; 2021 Dec; 29(12):1828-1837.e5. PubMed ID: 34784508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, immunogenicity, and safety of an oral influenza vaccine: a placebo-controlled and active-controlled phase 2 human challenge study.
    Liebowitz D; Gottlieb K; Kolhatkar NS; Garg SJ; Asher JM; Nazareno J; Kim K; McIlwain DR; Tucker SN
    Lancet Infect Dis; 2020 Apr; 20(4):435-444. PubMed ID: 31978354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity.
    Chua BY; Wong CY; Mifsud EJ; Edenborough KM; Sekiya T; Tan AC; Mercuri F; Rockman S; Chen W; Turner SJ; Doherty PC; Kelso A; Brown LE; Jackson DC
    mBio; 2015 Oct; 6(6):e01024-15. PubMed ID: 26507227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of heterosubtypic cross-protection against influenza by a whole inactivated virus vaccine: the role of viral membrane fusion activity.
    Budimir N; Huckriede A; Meijerhof T; Boon L; Gostick E; Price DA; Wilschut J; de Haan A
    PLoS One; 2012; 7(1):e30898. PubMed ID: 22303469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemagglutinin-specific CD4
    Tan S; Zhang S; Wu B; Zhao Y; Zhang W; Han M; Wu Y; Shi G; Liu Y; Yan J; Wu G; Wang H; Gao GF; Zhu F; Liu WJ
    Vaccine; 2017 Oct; 35(42):5644-5652. PubMed ID: 28917539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aerosol Delivery of a Candidate Universal Influenza Vaccine Reduces Viral Load in Pigs Challenged with Pandemic H1N1 Virus.
    Morgan SB; Hemmink JD; Porter E; Harley R; Shelton H; Aramouni M; Everett HE; Brookes SM; Bailey M; Townsend AM; Charleston B; Tchilian E
    J Immunol; 2016 Jun; 196(12):5014-23. PubMed ID: 27183611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Egg-based influenza split virus vaccine with monoglycosylation induces cross-strain protection against influenza virus infections.
    Tseng YC; Wu CY; Liu ML; Chen TH; Chiang WL; Yu YH; Jan JT; Lin KI; Wong CH; Ma C
    Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4200-4205. PubMed ID: 30782805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential Immunization With Live-Attenuated Chimeric Hemagglutinin-Based Vaccines Confers Heterosubtypic Immunity Against Influenza A Viruses in a Preclinical Ferret Model.
    Liu WC; Nachbagauer R; Stadlbauer D; Solórzano A; Berlanda-Scorza F; García-Sastre A; Palese P; Krammer F; Albrecht RA
    Front Immunol; 2019; 10():756. PubMed ID: 31105689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-immunization with tandem repeat heterologous M2 extracellular proteins overcomes strain-specific protection of split vaccine against influenza A virus.
    Lee YN; Kim MC; Lee YT; Kim YJ; Lee J; Kim C; Ha SH; Kang SM
    Antiviral Res; 2015 Oct; 122():82-90. PubMed ID: 26248203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
    Lei H; Peng X; Jiao H; Zhao D; Ouyang J
    Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seasonal influenza infection and live vaccine prime for a response to the 2009 pandemic H1N1 vaccine.
    Chen GL; Lau YF; Lamirande EW; McCall AW; Subbarao K
    Proc Natl Acad Sci U S A; 2011 Jan; 108(3):1140-5. PubMed ID: 21199945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Bivalent Heterologous DNA Virus-Like-Particle Prime-Boost Vaccine Elicits Broad Protection against both Group 1 and 2 Influenza A Viruses.
    Jiang W; Wang S; Chen H; Ren H; Huang X; Wang G; Chen Z; Chen L; Chen Z; Zhou P
    J Virol; 2017 May; 91(9):. PubMed ID: 28179535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Response and Protective Efficacy of Inactivated and Live Influenza Vaccines Against Homologous and Heterosubtypic Challenge.
    Boravleva EY; Lunitsin AV; Kaplun AP; Bykova NV; Krasilnikov IV; Gambaryan AS
    Biochemistry (Mosc); 2020 May; 85(5):553-566. PubMed ID: 32571185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination with recombinant 4 × M2e.HSP70c fusion protein as a universal vaccine candidate enhances both humoral and cell-mediated immune responses and decreases viral shedding against experimental challenge of H9N2 influenza in chickens.
    Dabaghian M; Latify AM; Tebianian M; Nili H; Ranjbar AR; Mirjalili A; Mohammadi M; Banihashemi R; Ebrahimi SM
    Vet Microbiol; 2014 Nov; 174(1-2):116-26. PubMed ID: 25293397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
    Mooney AJ; Gabbard JD; Li Z; Dlugolenski DA; Johnson SK; Tripp RA; He B; Tompkins SM
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28931689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-sterilizing, Infection-Permissive Vaccination With Inactivated Influenza Virus Vaccine Reshapes Subsequent Virus Infection-Induced Protective Heterosubtypic Immunity From Cellular to Humoral Cross-Reactive Immune Responses.
    Choi A; Ibañez LI; Strohmeier S; Krammer F; García-Sastre A; Schotsaert M
    Front Immunol; 2020; 11():1166. PubMed ID: 32582220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-Protection by Inactivated H5 Prepandemic Vaccine Seed Strains against Diverse Goose/Guangdong Lineage H5N1 Highly Pathogenic Avian Influenza Viruses.
    Criado MF; Sá E Silva M; Lee DH; Salge CAL; Spackman E; Donis R; Wan XF; Swayne DE
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32999029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influenza viruses and cross-reactivity in healthy adults: humoral and cellular immunity induced by seasonal 2007/2008 influenza vaccination against vaccine antigens and 2009 A(H1N1) pandemic influenza virus.
    Iorio AM; Bistoni O; Galdiero M; Lepri E; Camilloni B; Russano AM; Neri M; Basileo M; Spinozzi F
    Vaccine; 2012 Feb; 30(9):1617-23. PubMed ID: 22245606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans.
    Crowe BA; Brühl P; Gerencer M; Schwendinger MG; Pilz A; Kistner O; Koelling-Schlebusch K; Aichinger G; Singer J; Zeitlinger M; Müller M; Ehrlich H; Barrett PN
    Vaccine; 2010 Dec; 29(2):166-73. PubMed ID: 21055500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children.
    Forrest BD; Pride MW; Dunning AJ; Capeding MR; Chotpitayasunondh T; Tam JS; Rappaport R; Eldridge JH; Gruber WC
    Clin Vaccine Immunol; 2008 Jul; 15(7):1042-53. PubMed ID: 18448618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.